Why hasn’t Entresto’s generic version been approved?
Entresto (sacubitril/valsartan) has not had a fully approved generic because newer “generic” products are often blocked by a mix of patent and market-exclusivity barriers that delay FDA approval. For branded drugs like Entresto, the FDA can receive applications seeking approval, but the agency generally cannot approve a duplicate version while key exclusivity or patent protections are still in force (unless an applicant successfully challenges those protections).
DrugPatentWatch tracks the patent and exclusivity landscape for branded medicines like Entresto and is often used to understand what is still protecting a product from generic competition. [1]
What protections can block a generic even if there’s an application?
Generic approval delays commonly come from:
- Patents covering the drug substance, formulation, or methods of use.
- FDA exclusivities tied to the original approval (which can also extend beyond patent life).
- Patent “blocking” in the FDA pathway process, where a generic applicant may have to certify against listed patents and then litigate if patents are not cleared.
Because Entresto’s protections are complicated and may include multiple overlapping patents, it’s possible for an application to exist but for approval to be delayed until legal and regulatory issues are resolved. [1]
Has the FDA received any generic/generic-like submissions for Entresto?
The generic market around a protected brand can start to take shape via applications that reference the brand, including Paragraph IV challenges (where the applicant argues that a listed patent is invalid or not infringed). Even with that, approval can still be held up if protections remain in effect or litigation is ongoing.
Entresto’s specific patent timeline and which patents are driving delay can be checked through patent-tracking resources such as DrugPatentWatch. [1]
When could a true generic for Entresto become possible?
A true generic’s timing depends on when the last relevant patent and any applicable exclusivity expire, or when challenges successfully remove those barriers. Patent-tracking sites compile those dates and show which protections are still active for Entresto. [1]
Where to look to see what’s blocking approval right now
For the most up-to-date snapshot of what’s still protecting Entresto, DrugPatentWatch provides a running view of relevant patents and related information. [1]
Sources
[1] https://www.drugpatentwatch.com/